2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-14921
    Elsibucol 216167-95-2 99.35%
    Elsibucol is a VCAM1 inhibitor for the study of organ transplant rejection. Elsibucol is a metabolically stable propanol derivative with antioxidant, anti-inflammatory and anti-proliferative properties. Elsibucol lowers blood cholesterol levels and reduces oxidative stress and inflammatory responses in injured arteries, thereby inhibiting atherosclerosis and protecting endothelial healing after arterial injury.
    Elsibucol
  • HY-15492
    AG-13958 319460-94-1 99.71%
    AG-13958 (AG-013958), a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD).
    AG-13958
  • HY-16056
    Arbutamine 128470-16-6 ≥98.0%
    Arbutamine is a short-acting, potent and nonselective β-adrenoceptor agonist. Arbutamine stimulates cardiac β1-, tracheal β2-, and adiopocyte β3- adrenergic receptors. Arbutamine provides cardiac stress increases heart rate, cardiac contractility, and systolic blood pressure. Arbutamine can be used for cardiac stress agent .
    Arbutamine
  • HY-16316
    Metipranolol hydrochloride 36592-77-5 99.92%
    Metipranolol hydrochloride is a non-selective β adrenergic receptor blocking agent.
    Metipranolol hydrochloride
  • HY-16403
    Polythiazide 346-18-9 98.22%
    Polythiazide is a potent and orally active thiazide diuretic agent that has antihypertensive effect. Polythiazide can decrease edema and decrease blood pressure. Polythiazide also has phototoxicity.
    Polythiazide
  • HY-16952
    Bepridil 64706-54-3 98%
    Bepridil ((±)-Bepridil) is a calcium channel blocking agent used as antiarrhythmic agent. Bepridil inhibits both calcium and sodium currents, has research potential in certain ischemia-induced ventricular arrhythmias. Bepridil also has strong inhibition of SARS-CoV-2 from entry and replication inside Vero E6 and A549 cells.
    Bepridil
  • HY-18730
    1400W 180001-34-7 98%
    1400W is a slow, tight binding, and highly selective inducible nitric-oxide synthase (iNOS) inhibitor, with a Kd value ≤ 7 nM. 1400W inhibits iNOS induction in microglial cells, and reduces generation of NO, thereby mitigating oxidative stress and neuronal cell apoptosis in the rat cerebral cortex, and improving the spatial memory dysfunction caused by acute hypobaric hypoxia-reoxygenation.
    1400W
  • HY-18734
    Carboxy-PTIO 145757-47-7 98%
    Carboxy-PTIO is a potent nitric oxide (NO) scavenger that can make a quick reaction with NO to produce NO2. Carboxy-PTIO can prevent hypotension and endotoxic shock through the direct scavenging action against NO in lipopolysaccharide-stimulated rat model.
    Carboxy-PTIO
  • HY-19094
    DuP-532 124750-95-4 98.00%
    DuP-532 is an angiotensin type 1 receptor antagonist with potential activity in the suppression of hypertension and heart failure. DuP-532 can react with a range of aryl and heteroaryl halides to form perfluoroalkyl(hetero)arenes in moderate to high yields. Computational studies of DuP-532 suggest that coordination of a second phenyl ring ligand may lower the energy barrier for decarboxylation of perfluorocarboxylates, thereby promoting the perfluoroalkylation reaction.
    DuP-532
  • HY-19529
    Ro 46-2005 150725-87-4 98.32%
    Ro 46-2005 is a novel synthetic non-peptide endothelin receptor antagonist, inhibits the specific binding of 125I-ET-1 to human vascular smooth muscle cells (ETA receptor) with IC50 of 220 nM.
    Ro 46-2005
  • HY-19886
    F 16915 92510-91-3 98.16%
    F 16915, a Docosahexaenoic Acid (DHA, HY-B2167) derivative, is a potent pro-agent of DHA. F 16915 can prevent heart failure-induced atrial fibrillation.
    F 16915
  • HY-21796
    1-Methyl-3-phenylpropylamine 22374-89-6 99.71%
    ELA-32(human) is a potent critical cardiac developmental peptide that acts through the G-protein–coupled apelin receptor.
    1-Methyl-3-phenylpropylamine
  • HY-22044
    ICA 3374-88-7 99.92%
    ICA (N-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine) is a SK channel inhibitor that has antileishmanial activity with an IC50 of 2.1 µM.
    ICA
  • HY-76573
    ML-10 1216897-16-3
    ML-10 is a small molecule apoptosis probe. Due to the presence of fluorine atoms, ML-10 can be radiolabeled with 18F isotopes and can be used for apoptosis positron emission tomography imaging studies. ML-10 is selectively taken up and accumulated in apoptotic cells, while being excluded from live or necrotic cells. In addition, the uptake of ML-10 is associated with apoptotic features such as caspase activation, Annexin-V binding, and disruption of mitochondrial membrane potential.
    ML-10
  • HY-78841
    (2S,4S)-Sacubitril 149709-63-7
    (2S,4S)-Sacubitril is the impurity of Sacubitril. Sacubitril is a potent NEP inhibitor that can be used for the research of heart failure.
    (2S,4S)-Sacubitril
  • HY-A0116
    Trandolaprilate 87679-71-8 98%
    Trandolaprilate is a potent angiotensin-converting enzyme (ACE) inhibitor. Trandolaprilate partially inhibits angiotensin-I-mediated c-fos induction. Trandolaprilate is main bioactive metabolite of Trandolapril. Trandolaprilate shows high lipophilicity.
    Trandolaprilate
  • HY-B0162
    Ivabradine 155974-00-8 98%
    Ivabradine is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine reduces dose-dependently heart rate without modification of blood pressure. Ivabradine shows anticonvulsant, anti-ischaemic and anti-anginal activity.
    Ivabradine
  • HY-B0197
    Naratriptan 121679-13-8 98.05%
    Naratriptan is an orally active and selective 5-HT1B/1D receptor agonist. Naratriptan is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC50=0.11 μM for dog basilar artery). Naratriptan also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms.
    Naratriptan
  • HY-B0292
    Atracurium 64228-79-1 98%
    tracurium (BW-33A free acid) is a potent, competitive and non-depolarizing neuromuscular blocking agent.Atracurium also is an AChR receptor antagonist. Atracurium induces bronchoconstriction and neuromuscular blockade. Atracurium promotes astroglial differentiation.
    Atracurium
  • HY-B0374
    Moxonidine 75438-57-2 99.72%
    Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I1-R) agonist. Moxonidine activates imidazoline I1 receptors and α2 adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis.
    Moxonidine
Cat. No. Product Name / Synonyms Application Reactivity